<DOC>
	<DOCNO>NCT02313077</DOCNO>
	<brief_summary>The purpose study test safety immunogenicity MVA-BN-Filo Ad26.ZEBOV heterologous prime-boost vaccine regimens healthy adult participant .</brief_summary>
	<brief_title>A Safety Immunogenicity Study Heterologous Prime-Boost Ebola Vaccine Regimens Healthy Participants</brief_title>
	<detailed_description>This first-in-human study consist 2 part : 1 ) The main study , randomize , placebo-controlled , observer-blind ; 2 ) A sub-study , open-label , uncontrolled , non-randomized study evaluate safety , tolerability , immunogenicity MVA-BN-Filo Ad26.ZEBOV administer different sequence schedule healthy adult participant . The study consist Screening period ( 28 day main study 56 day sub-study ) , vaccination period participant vaccinate baseline ( Day 1 ) follow boost Day 15 , 29 57 , post-boost follow-up participant 21-day post-boost visit ( Day 36 , 50 Day 78 ) . The total duration study 1 year participant receive vaccine 3 month participant receive placebo . Safety monitor study .</detailed_description>
	<criteria>Must healthy basis physical examination , medical history , investigator 's clinical judgment Women childbearing potential must negative serum βhuman chorionic gonadotropin pregnancy test screening , negative urine pregnancy test immediately prior study vaccine administration , practice adequate birth control measure 28 day prime vaccination least 3 month boost vaccination specify study protocol . If heterosexually active screening , must agree practice adequate birth control measure become heterosexually active participation study ( screen onwards least 3 month boost vaccination ) . Agree donate egg ( ovum , oocytes ) purpose assist reproduction screen onwards least 3 month boost vaccination Women nonchildbearing potential , define postmenopausal ( &gt; 45 year age amenorrhea ≥2 year age amenorrhea ≥6 month serum folliclestimulating hormone [ FSH ] &gt; 40 mIU/mL ) surgically sterile ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) , require use birth control method specify study protocol A man sexually active woman childbearing potential vasectomy must agree use doublebarrier method birth control , either condom spermicidal foam/gel/film/cream/suppository partner occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository . In case female partner use adequate method birth control , singlebarrier method birth control male subject acceptable . Men must also agree donate sperm screen onwards least 3 month boost vaccination Must available willing participate duration study visit followup , provide verifiable identification , mean contact Has vaccinate candidate Ebola vaccine Has diagnose Ebola disease expose Ebola include travel West Africa last 12 month . West Africa include limited country Guinea , Liberia , Mali , Sierra Leone Has receive Ad26 MVAbased candidate vaccine past Known allergy history anaphylaxis serious adverse reaction vaccine vaccine product ( include constituent study vaccine ) , include know allergy egg aminoglycosides A woman pregnant breastfeeding , plan become pregnant enrolled study within 3 month boost vaccination History diabetes mellitus type 1 type 2 , include case control diet alone ; thyroidectomy , thyroid disease require medication last 12 month ; uncontrolled hypertension define study protocol ; , major psychiatric illness and/or substance abuse problem past 12 month opinion investigator would preclude participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Ebola virus</keyword>
	<keyword>Ebola Viral Disease ( EVD )</keyword>
	<keyword>Filoviruses</keyword>
	<keyword>monovalent vaccine</keyword>
	<keyword>Human adenovirus serotype 26 ( Ad26 ) express Ebola virus Mayinga variant glycoprotein ( Ad26.ZEBOV )</keyword>
	<keyword>Modified Vaccinia Virus Ankara - Bavarian Nordic ( MVA-BN ) Filo-vector</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>